These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26612851)

  • 21. Perceptions of the usefulness of external support to immunization coverage in Chad: an analysis of the GAVI-Alliance cash-based support.
    Ferrinho P; Dramé M; Tumusiime P
    Pan Afr Med J; 2013; 15():44. PubMed ID: 24106572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pro-equity immunization and health systems strengthening strategies in select Gavi-supported countries.
    Dadari I; Higgins-Steele A; Sharkey A; Charlet D; Shahabuddin A; Nandy R; Jackson D
    Vaccine; 2021 Apr; 39(17):2434-2444. PubMed ID: 33781603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A global health partnership's use of time-limited support to catalyze health practice change: the case of GAVI's Injection Safety Support.
    Levin A; Fang A; Hansen PM; Pyle D; Dia O; Schwalbe N
    PLoS One; 2010 Sep; 5(9):e12986. PubMed ID: 20885995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance-based financing with GAVI health system strengthening funding in rural Cambodia: a brief assessment of the impact.
    Matsuoka S; Obara H; Nagai M; Murakami H; Chan Lon R
    Health Policy Plan; 2014 Jul; 29(4):456-65. PubMed ID: 23735736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GAVI and the Vaccine Fund--a boon for immunization in the developing world.
    Balaji KA
    Indian J Public Health; 2004; 48(2):45-8. PubMed ID: 15709583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Tale of 2 Countries: Implementation of the Cold Chain Equipment Optimization Platform in Guinea and Kenya.
    Stammer E; Teklemariam L; Barry A; Millimono R; Chweya A; Danfakha N; Golia C; Herrera E; Patykewich L; Prosser W; Alva S
    Glob Health Sci Pract; 2022 Oct; 10(5):. PubMed ID: 36316144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postneonatal mortality impacts following grants from the Gavi Vaccine Alliance: an econometric analysis from 2000 to 2014.
    Kolesar RJ; Audibert M
    Public Health; 2017 Dec; 153():163-171. PubMed ID: 29102832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An analysis of GAVI, the Global Fund and World Bank support for human resources for health in developing countries.
    Vujicic M; Weber SE; Nikolic IA; Atun R; Kumar R
    Health Policy Plan; 2012 Dec; 27(8):649-57. PubMed ID: 22333685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An approach to health system strengthening in the Union of Myanmar.
    Tin N; Lwin S; Kyaing NN; Htay TT; Grundy J; Skold M; O'Connell T; Nirupam S
    Health Policy; 2010 May; 95(2-3):95-102. PubMed ID: 20015569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving district facility readiness: a 12-month evaluation of a data-driven health systems strengthening intervention in rural Rwanda.
    Iyer HS; Kamanzi E; Mugunga JC; Finnegan K; Uwingabiye A; Shyaka E; Niyonzima S; Hirschhorn LR; Drobac PC
    Glob Health Action; 2015; 8():28365. PubMed ID: 26140729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
    Lydon P; Levine R; Makinen M; Brenzel L; Mitchell V; Milstien JB; Kamara L; Landry S
    Vaccine; 2008 Dec; 26(51):6706-16. PubMed ID: 18952134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating Global Health Partnerships: A Case Study of a Gavi HPV Vaccine Application Process in Uganda.
    Kamya C; Shearer J; Asiimwe G; Carnahan E; Salisbury N; Waiswa P; Brinkerhoff J; Hozumi D
    Int J Health Policy Manag; 2017 Jun; 6(6):327-338. PubMed ID: 28812825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The GAVI Financing Task Force: one model of partner collaboration.
    Milstien JB; Kamara L; Lydon P; Mitchell V; Landry S
    Vaccine; 2008 Dec; 26(51):6699-705. PubMed ID: 19306508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seizing market shaping opportunities for vaccine cold chain equipment.
    Azimi T; Franzel L; Probst N
    Vaccine; 2017 Apr; 35(17):2260-2264. PubMed ID: 28364940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance.
    Gilchrist SA; Nanni A
    Health Policy Plan; 2013 Dec; 28(8):838-46. PubMed ID: 23174880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investing in health systems for universal health coverage in Africa.
    Sambo LG; Kirigia JM
    BMC Int Health Hum Rights; 2014 Oct; 14():28. PubMed ID: 25345988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An approach to health system strengthening in the Democratic Peoples Republic of Korea (North Korea).
    Grundy J; Moodie R
    Int J Health Plann Manage; 2009; 24(2):113-29. PubMed ID: 18645987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization.
    Kane MA; Hadler SC; Lee L; Shapiro CN; Cui F; Wang X; Kumar R
    Vaccine; 2013 Dec; 31 Suppl 9():J15-20. PubMed ID: 24331015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ensuring vaccine potency and availability: how evidence shaped Gavi's Immunization Supply Chain Strategy.
    Prosser W; Sagar K; Seidel M; Alva S
    BMC Health Serv Res; 2022 Oct; 22(1):1237. PubMed ID: 36207724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GAVI's challenges: funding and leadership.
    Lancet; 2010 Oct; 376(9751):1438. PubMed ID: 21036259
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.